表紙
市場調査レポート

米国の癌ワクチン市場の分析

US Cancer Vaccine Market Outlook 2022

発行 RNCOS E-Services Pvt. Ltd. 商品コード 250707
出版日 ページ情報 英文 135 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
米国の癌ワクチン市場の分析 US Cancer Vaccine Market Outlook 2022
出版日: 2016年07月01日 ページ情報: 英文 135 Pages
概要

当レポートでは、米国における癌ワクチン市場の現状と将来展望について分析し、米国の現在のがん発症状況、癌ワクチン市場の構造・特性、主な製品の開発・販売状況、市場規模の予測値、今後の市場機会、現在の規制環境、主要企業のプロファイル(事業内容・主要戦略分析)などを調査・推計しています。

第1章 アナリストの見解

第2章 分析手法

第3章 癌患者人口の統計

  • 発症率・有病率・死亡率
  • 発症率の上位の州
  • 主な癌の発症率
    • 男性の癌発症率
    • 女性の癌発症率
    • 子供の癌発症率

第4章 市場力学

  • 成長因子
  • 成長阻害因子
  • 機会

第5章 癌ワクチン市場の見通し

  • 主要製品の分析
    • Provenge
    • T-Vec/Imlygic
    • ヒトパピローマウイルス (HPV) ワクチン
    • B型肝炎ウイルス (HBV) ワクチン

第6章 癌の種類別の癌ワクチン市場

第7章 用途別の癌ワクチン市場

第8章 癌ワクチンの将来的な候補:市場機会の評価

  • 予防ワクチン
  • 治療ワクチン
    • 前立腺癌
    • 乳癌
    • 肺癌
    • 大腸癌

第9章 米国の特許分析

第10章 規制環境

  • ワクチンの認証過程
  • 米国食品医薬品局 (FDA) の業界向けガイドライン:治療用癌ワクチンの治験時の考慮事項
    • 治験の初期・後期の両段階における考慮事項
    • 治験の初期段階における考慮事項
    • 治験の後期段階における考慮事項

第11章 競争環境

第12章 企業プロファイル

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Cancer is one of the major health issues faced by the countries across the globe. The researchers are engaged in developing various drugs for the prevention and treatment of the disease. Cancer vaccine is one such example. Since their inception, cancer vaccines were considered as high potential method for preventing and treating cancer. Till date, the vaccines have not been able to achieve the expected sales due to high cost and negative results in clinical trials. However, with launch of new cancer vaccines, such as Imlygic by Amgen; and increasing awareness of people regarding these vaccines, the market is expected to grow.

The US is largest market for cancer vaccines. The growth of the US cancer vaccine market is driven by increasing cancer incidence in the country, rising awareness, and strong pipeline. The “US Cancer Vaccine Market Outlook 2022” report provides detailed analysis of the market. This report covers the present scenario and the growth prospects of US cancer vaccine market for the period 2015-2022. It also covers the drivers, restraints hampering the growth of the market, and future opportunities. Moreover, the report provides the global sales of various cancer vaccines from 2013-2015.

On the basis of type of cancer for which the vaccine is targeted, the market has been segmented into three types, namely, liver cancer, HPV related cancer, and others. Currently, HPV related cancer vaccines occupy the largest share in the US market.

On the basis of type of vaccine, the market has been further sub-divided into prophylactic vaccines and therapeutic vaccines. The prophylactic vaccines accounts for the largest share in 2016. The large share of this market is attributed to various vaccination programs organized by the US government for prevention against HPV and hepatitis. The therapeutic vaccines are expected to witness high growth in coming years due to strong pipeline. Amongst the various research studies, a vaccine for lung cancer can be expected to come up soon with promising candidates, such as TV4010 and GV1001, having entered phase 3 trials.

The report also provides market share analysis by key players. Merck and GSK are expected to continue to be undisputed market leaders in the cancer vaccine market. Furthermore, the report also covers the FDA's vaccine approval procedure, and its guidance to the industry for developing therapeutic cancer vaccines. Additionally, the report also enlists the pipeline of cancer vaccines which are in various clinical trial phases. The patent analysis of products in US has also been added in the report on the basis of year of grant, type of patent, and assignee of the patent.

The last section of the report discusses about the key players in the US cancer vaccine market. A brief business overview and financial information about each of these players has been provided in the report. Moreover, this report will help the reader to gain crucial insight into the key players' performances and strategies for growth. Conclusively, the research will prove to be a useful resource for all debut makers in US cancer vaccine industry and potential investors.

Table of Contents

1. Analyst View

2. Research Methodology

3. Cancer Statistics by Demographics

  • 3.1. Prevalence, Incidences and Mortality
  • 3.2. Leading States by Incidences
  • 3.3. Leading Cancers by Incidences
    • 3.3.1. Male Cancer Incidences
    • 3.3.2. Female Cancer Incidences
    • 3.3.3. Children Cancer Incidences

4. Market Dynamics

  • 4.1. Drivers
    • 4.1.1. Rising Cancer Incidences
    • 4.1.2. Ability to Reduce Healthcare Expenditure
    • 4.1.3. Rising Awareness
    • 4.1.4. Patient Assistance Programs
    • 4.1.5. Government Initiatives
    • 4.1.6. Strong Pipeline
    • 4.1.7. Technological Advancements
  • 4.2. Restraints
    • 4.2.1. High Cost of Cancer Vaccines
    • 4.2.2. Side Effects of Cancer Vaccines
    • 4.2.3. Vaccine Supply Shortages
    • 4.2.4. Insurance Issues Related to Cancer Vaccination
  • 4.3. Opportunities
    • 4.3.1. Therapeutic Cancer Vaccines
    • 4.3.2. Adjuvant Cancer Vaccines

5. Cancer Vaccines Market Outlook

  • 5.1. Key Product Analysis
    • 5.1.1. Provenge
      • 5.1.1.1. Market Analysis
    • 5.1.2. T-Vec/Imlygic
      • 5.1.2.1. Market Analysis
    • 5.1.3. HPV Vaccine
      • 5.1.3.1. Gardasil
        • 5.1.3.1.1. Market Analysis
      • 5.1.3.2. Cervarix
        • 5.1.3.2.1. Market Analysis
    • 5.1.4. HBV Vaccines
      • 5.1.4.1. Engerix-B
        • 5.1.4.1.1. Market Analysis
      • 5.1.4.2. Recombivax HB
        • 5.1.4.2.1. Market Analysis
      • 5.1.4.3. Pediarix/ Infanrix
        • 5.1.4.3.1. Market Analysis

6. Cancer Vaccines Market by Cancer Type

7. Cancer Vaccine Market by Application

8. Potential Cancer Vaccine Candidates: An Opportunity Assessment

  • 8.1. Prophylactic Vaccine
  • 8.2. Therapeutic Vaccine
    • 8.2.1. Prostate Cancer
    • 8.2.2. Breast Cancer
    • 8.2.3. Lung Cancer
    • 8.2.4. Colorectal Cancer

9. US Patent Analysis

  • 9.1. Patents by Year
  • 9.2. Patents by Category
    • 9.2.1. Utility Patents
    • 9.2.2. Design Patents
    • 9.2.3. Plant Patents
  • 9.3. Patents by Company
  • 9.4. Patents by Assignee Type
    • 9.4.1. By Assignee Name
    • 9.4.2. By Assignee State

10. Regulatory Environment

  • 10.1. Vaccine Approval Process
  • 10.2. FDA Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines
    • 10.2.1. Considerations for both Early and Late Phase Clinical Trials
      • 10.2.1.1. Patient Population
      • 10.2.1.2. Monitoring the Immune Response
      • 10.2.1.3. Biomarkers as Evidence of Efficacy
      • 10.2.1.4. Adjuvants Used to Stimulate Immune Response
      • 10.2.1.5. Multi-antigen Vaccines
      • 10.2.1.6. Disease Progression/Recurrence Immediately or Shortly
        • after the Initial Administration of Cancer Vaccines
      • 10.2.1.7. Concomitant and Subsequent Therapies
    • 10.2.2. Considerations for Early Phase Clinical Trials
      • 10.2.2.1. Starting Dose and Dosing Schedule
      • 10.2.2.2. Booster and Maintenance Therapy
      • 10.2.2.3. Dose Escalation
      • 10.2.2.4. Single-arm versus Randomized Phase-2 Trials in Early
        • Development
    • 10.2.3. Considerations for Late Phase Clinical Trials
      • 10.2.3.1. Safety Profile from Early Phase Clinical Trials
      • 10.2.3.2. Endpoints
      • 10.2.3.3. Statistical Issues
      • 10.2.3.4. Control Issues
      • 10.2.3.5. Delayed Vaccine Effect
      • 10.2.3.6. Autologous Vaccine Trials
      • 10.2.3.7. Accelerated Approval Regulations

11. Competitive Landscape

12. Company Profiles

  • 12.1. Merck & Co.
  • 12.2. GlaxoSmithKline plc
  • 12.3. Dendreon (A Subsidiary of Valeant Pharmaceuticals)
  • 12.4. Amgen Inc.

List of Figures:

  • Figure 3-1: Cancer Incidences (Million), 2015-2022
  • Figure 3-2: Cancer Mortality (Million), 2015-2022
  • Figure 3-3: Incidences by Type of Cancer (%), 2016
  • Figure 3-4: States with Highest Cancer Incidences, 2015
  • Figure 5-1: Share of US in Global Cancer Vaccine Market (%), 2016
  • Figure 5-2: US - Cancer Vaccine Market by Product Type (%), 2016
  • Figure 5-3: Global - Provenge Market (Million US$), 2013-2015
  • Figure 5-4: Share of US in Global Imlygic Sales (%), 2015
  • Figure 5-5: Global - Gardasil Market (Million US$), 2013-2015
  • Figure 5-6: US - Gardasil Market (Million US$), 2013-2015
  • Figure 5-7: Share of US in Global Gardasil Sales (%), 2015
  • Figure 5-8: Global - Cervarix Market (Million US$), 2013-2015
  • Figure 5-9: US - Cervarix Market (Million US$), 2013-2015
  • Figure 5-10: Share of US in Global Cervarix Sales (%), 2015
  • Figure 5-11: Global - Engerix-B Market (Million US$), 2013-2015
  • Figure 5-12: US - Engerix-B Market (Million US$), 2013-2015
  • Figure 5-13: Share of US in Global Engerix-B Sales (%), 2015
  • Figure 5-14: Global - Recombivax HB Market (Million US$), 2013-2015
  • Figure 5-15: US - Recombivax HB Market (Million US$), 2013-2015
  • Figure 5-16: Share of US in Global Recombivax HB Sales (%), 2015
  • Figure 5-17: Global - Pediarix/Infanrix Market (Million US$), 2013-2015
  • Figure 5-18: US - Pediarix/ Infanrix Market (Million US$), 2013-2015
  • Figure 5-19: Share of US in Global Pediarix/Infanrix Sales (%), 2015
  • Figure 6-1: US - Cancer Vaccine Market by Cancer Type (%), 2016
  • Figure 6-2: US - Cancer Vaccine Market for Liver Cancer (Million US$), 2015-2022
  • Figure 6-3: US - Cancer Vaccine Market for HPV Related Cancer (Million US$), 2015-2022
  • Figure 6-4: US - Cancer Vaccine Market for Other Cancers (Million US$), 2015-2022
  • Figure 7-1: US - Cancer Vaccine Market by Application (%), 2016
  • Figure 7-2: US - Cancer Vaccine Market for Therapeutic Vaccines (Million US$), 2015-2022
  • Figure 7-3: US - Cancer Vaccine Market for Prophylactic Vaccines (Million US$), 2015-2022
  • Figure 8-1: Prophylactic Cancer Vaccines in Clinical Trials by Cancer Site (%), 2016
  • Figure 8-2: Prophylactic Cancer Vaccines in Clinical Trials by Phases (%), 2016
  • Figure 8-3: Therapeutic Cancer Vaccines in Clinical Trials by Cancer Site (%), 2016
  • Figure 8-4: Therapeutic Cancer Vaccines in Clinical Trials by Phases (%), 2016
  • Figure 8-5: Cancer Vaccines in Clinical Trials by Application (%), 2016
  • Figure 11-1: US - Share of Major Players in Cancer Vaccine Market (%), 2015
  • Figure 12-1: Merck & Co. - Breakup of Revenue by Segment (%), 2015
  • Figure 12-2: GlaxoSmithKline - Breakup of Revenue by Segment (%), 2015
  • Figure 12-3: Valeant Pharmaceuticals International, Inc. - Breakup of Revenue by Segment (%), 2015

List of Tables:

  • Table 3-1: Top 10 Cancer Incidences in Males (2015)
  • Table 3-2: Top 10 Cancer Incidences in Females (2015)
  • Table 3-3: Top 10 Cancer Incidences in Children (Ages 0-14), (2015)
  • Table 4-1: US - Cancer Incidences (Million), 2015 & 2020
  • Table 5-1: Global - Cancer Vaccine Market (Million US$), 2015-2022
  • Table 5-2: US - Cancer Vaccine Market (Million US$), 2015-2022
  • Table 8-1: Cancers with High Linkage to Virus and Bacteria
  • Table 8-2: Prophylactic Cancer Vaccines in Clinical Trials
  • Table 8-3: Therapeutic Cancer Vaccines in Clinical Trials
  • Table 8-4: Prostate Cancer Therapeutic Vaccines in Clinical Trials
  • Table 8-5: Breast Cancer Therapeutic Vaccines in Clinical Trials
  • Table 8-6: Lung Cancer Therapeutic Vaccines in Clinical Trials
  • Table 8-7: Colorectal Cancer Therapeutic Vaccines in Clinical Trials
  • Table 12-1: Merck & Co. - Key Financials (Million US$), 2013-2015
  • Table 12-2: Merck - Product Portfolio
  • Table 12-3: Merck - Cancer Vaccines in Pipeline
  • Table 12-4: GlaxoSmithKline - Key Financials (Million US$), 2013-2015
  • Table 12-5: GlaxoSmithKline - Product Portfolio
  • Table 12-6: GlaxoSmithKline - Cancer Vaccines in Pipeline
  • Table 12-7: Valeant Pharmaceuticals International, Inc. - Key Financials (Million US$), 2013-2015
  • Table 12-8: Dendreon - Product Portfolio
  • Table 12-9: Amgen Inc. - Key Financials (Million US$), 2013-2015
  • Table 12-10: Amgen Inc. - Product Portfolio
Back to Top